Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  PledPharma AB (publ)    PLED   SE0003815604

News SummaryMost relevantAll newsSector newsTweets

PledPharma publ : The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

share with twitter share with LinkedIn share with facebook
share via e-mail
09/14/2017 | 01:46pm CET

The data safety monitoring committee gave the approval to initiate the next cohort in the open-label, randomised, rising dose design, proof-of-principle safety and tolerability study with Aladote in patients treated with NAC for paracetamol overdose.       

The study is conducted at the University of Edinburgh, Queen’s Medical Research Institute in Scotland and will involve a total of 24 patients assigned into one of 3 dosing cohorts of 8 patients.

The first cohort receiving the lowest dose of the study drug has been completed and after reviewing the safety data the monitoring committee, in a meeting held on September 13, approved to continue with recruitment for the middle dose group.


For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]

Michaela Gertz, CFO, phone: +46 709 26 17 75
[email protected]

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se


Copyright © 2017 OMX AB (publ), source OMX

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PLEDPHARMA AB (PUBL)
08:04a PLEDPHARMA PUBL : Phase IIb study with PledOx® (PLIANT) published in Acta Oncolo..
11/16 PLEDPHARMA PUBL : initiates Phase III studies with PledOx® before year end 2017
11/07 PLEDPHARMA PUBL : appoints Yilmaz Mahshid as new CFO
10/25 PLEDPHARMA PUBL : Nomination Committee for the 2018 Annual General Meeting in Pl..
10/05 PLEDPHARMA PUBL : Principal investigator of Aladote study James Dear presents ca..
10/04 PLEDPHARMA PUBL : Principal investigator of Aladote® study James Dear presents c..
09/15 PLEDPHARMA PUBL : CFO to leave the company in December 2017
09/14 PLEDPHARMA PUBL : The Aladote study in patients treated for paracetamol overdose..
08/30 PLEDPHARMA PUBL : Interim report January - June 2017
08/25 PLEDPHARMA PUBL : establishes a Scientific Advisory Board for the continued clin..
More news
Financials ( SEK)
Sales 2017 -
EBIT 2017 -67,0 M
Net income 2017 -66,8 M
Finance 2017 330 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 0
EV / Sales 2018 0
Capitalization 730 M
Income Statement Evolution
EPS Revisions
Jacques Näsström Chief Executive Officer
Håkan Åström Chairman
Michaela Johansson Gertz Chief Financial Officer
Stefan Carlsson Chief Medical Officer & VP-Clinical Development
Magnus Andreas Bunge Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB-3.41%11 744
EXELIXIS, INC.66.00%7 642